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ABSTRACT 
BACKGROUND : 
Second most common cancer related death worldwide. There is change 
in the site of occurance of gastric cancer, there is increase in occurance of 
proximal tumours than the distal tumours. 
OBJECTIVES : 
Study was undertaken in GMKMCH Salem, to study the prevalence, 
clinical features, association of risk factors, site of occurance and 
histopathology. 
METHODS : 
All patients with histopathology confirmed as stomach carcinoma was 
studied and details regarding clinical feautures, subsites, pathology, 
investigations and treatment modalities was collected. 
RESULTS : 
36 Patients with histology confirmation of stomach carcinoma was 
studied. There is a increase in male preponderance and old age. Association of 
risk factors was studied. Majority are present with distal tumours and in 
advanced stage. 
 
INTERPRETATION AND CONCLUSION : 
Stomach carcinoma is commonly seen in old age with male 
preponderance. Patients are mostly present in advanced stage. But the use of 
endoscopy early gastric cancers can be identified. Association of risk factors is 
well known and can be used in promodial prevention of disease. Despite of 
increase in proximal tumours in west , Distal tumours predominate in our 
study. 
KEY WORDS 
Stomach carcinoma, fundus, body, OG junction, antrum, gastrectomy, 
jejunostomy, chemotherapy, radiotherapy 
  
AIMS AND OBJECTIVES OF THE STUDY 
The Study was conducted based on following principles. 
9 To Study the anatomical location of tumour with respect to age 
and sex distribution. 
9 To Study the Etiology and Risk factors. 
9 To Study the classification of tumours based on morphology. 
9 To Study the symptoms and signs with respect to tumour 
location. 
9 To Study the various investigation modalities and its sensitivity 
and specificity . 
9 To Study the Histopathological type in relation to site of tumour. 
9 To Study the Surgical modalities of treatment. 
 
 
 
 
 
 
INTRODUCTION 
In the 21st century, Adenocarcinoma of stomach was one of the leading 
cause of cancer related death throughout the world.  Adenocarcinoma stands 
second to lung cancer in causing cancer related deaths worldwide. Annually 
about 9,88,000 cases of the stomach was diagnosed world wide & estimated 
number of deaths was 4,50,000 .Stomach cancer has a geographical incidence 
due to diet modification, preparation of food & various environmental factors. 
Incidence of the carcinoma stomach is very low is India, but in most 
metropolitan cities stomach carcinoma was  one of the 10 leading sites of 
cancer in both men & women.  In India incidence of the stomach cancer is 
increasing due to migration to cities from rural population, lifestyle 
modification & increase in life expectancy. 
One of the factor responsible for changing incidence rate is due to 
change in diet. In India there is diversity in diet unknown to most other 
countries, due to religious & cultural teachings in diet, executed for thousands 
of years, However role of Indian diet is causation or prevention of stomach 
cancer is little known, hence more attention is followed on some diet aspects 
such as vegetarianism, spices & food additives.  
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The stomach cancer has poor prognosis, except in some countries, poor 
prognosis due to multiple factors.  Because of absence of definite risk factors, 
lack of symptoms specific & low incidence has contributed to delay in 
diagnosing at an earlier stage, leads to late diagnosis.  But in Japan, since the 
stomach carcinoma is endemic, most of patients are diagnosed at earlier  stage, 
this leads to increase in overall survival rates. 
Overall  incidence of stomach cancer is decreased over the past decades, 
the decrease is mainly due to the cancers arising below the esophagogastric 
junction.  However the incidence of new cases of proximal gastric carcinomas 
arising is increasing. They are usually more aggressive and the treatment of 
such tumours is also very difficult. 
The only definitive treatment for Gastric cancer is to remove the cancer 
both micro and macroscopically by surgical intervention.  However even after 
complete curative treatment, disease is recurring in local or at distant region, in 
most of the patients.  Hence now it is focusing on development of systemic and 
regional adjuvant therapies given pre and postoperatively. 
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EPIDEMIOLOGY : 
Stomach cancer incidence is increasing in age. Peak incidence occurs in 
age between 60-80 years of age. In India age ranges from 35 – 55 yrs in south  
and 45-55 yrs in north. The disease shows a male preponderance in almost all 
countries. Two to four times higher in males than the females. The incidence of 
gastric cancer varies in various parts of the world. High incidence is seen in 
south eastasia, Europe and south America. Recent assessment of 5,56,000 
deaths in cancer in India in 2010 based on National representative survey 
shows that Stomach cancer is the Second most fatal cancer in India. 
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REVIEW OF LITERATURE 
 HISTORY :    
1st case of GASTRIC CANCER…1600 BC reported by Ebers papyrus. 
Benign and malignant gastric ulcer reported by J.Cruveilhier in 1835. 
Clinical  picture of symptoms of gastric cancer reported by Bayle in 
1839. 
First Gastric resection for cancer. Jules  Emiley Pean in 1879. 
First successful subtotal resection with gastro duodenal anastamosis. 
THEODER BILLROTH IN 22 JAN 1881. 
First Total Gatrectomy.. Karl Schlatter in 1897. 
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ANATOMY 
Stomach lies  in the upper & left part of abdomen.  It occupies 
epigastric, umbilical & hypogastric region. 
- Stomach is divided into, two parts (cardiac & pyloric) division by 
line drawn downwards and to the left from Incisura angularis. 
CARDIAC PART:- 
Subdivided   into  Fundus & body 
1. Fundus    :- 
- Upper convex dome shaped region. 
- Situated above the horizontal line which was drawn at level of 
cardiac orifice. 
2.  Body:- 
- The portion that lies between the fundus and pyloric part is called 
body. 
PYLORIC PART:- 
- Subdivided into pyloric antrum and pyloric canal. 
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1. Pyloric antrum:- 
- About 3 inches long 
- Seperated from pyloric canal by inconstant sulcus 
Intermedius. 
2.  Pyloric canal:- 
- 1 inch long, narrow and tubular curvatures of stomach. 
  Greater curvatures:- 
Convex, forms left border of stomach provides attachment to greater 
omentum, gastrosplenic and   gastrophrenic ligaments. 
Lesser curvature : 
Concave, forms right border of stomach, provides attachment to lesser 
omentum. Incisuraangularis or angular notch is the most dependent part of 
lesser  omentum . 
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PIC8.   STOMACH AND ITS DIVISIONS 
 
 
RELATIONS  OF STOMACH :-  
PERITONAL RELATIONS :- 
Both anterior and posterior surfaces are lined  by peritoneum  At level of 
lesser curvature it meets &become lesser omentum. Near the cardiac end it 
gives attachment to form  gastrosplenic  ligament  
Near cardiac end on posterior surface attachment for gastrophrenic 
ligament. 
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VISCERAL RELATIONS:-  
Anterior part :-  
1. Liver 
2. The diaphragm 
3. Anterior abdominal wall 
Posterior Part :- 
1. The Diaphragm 
2. The left kidney 
3. The left suprarenal gland 
4. Pancreas 
5. Splenic flexure of colon 
6. Splenic artery 
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Blood supply :- 
              Blood supply of stomach is mainly from vessels arising from 
celiac plexus 
PIC 9. BLOOD SUPPLY OF STOMACH 
 
LEFT GASTRIC ARTERY :- 
Arises  directly from celiac axis course along lesser curvature. It divides 
is to anterior and posterior branch before reaching lesser curvature  
Cardioesophagial artery arises from anterior branch. After giving this 
branch, it curves downwards and to right along the lesser curvature. During it 
descends it divides into anterior and posterior branch supplying anterior and 
posterior gastric wall. 
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RIGHT GASTRIC ARTERY;- 
Small branch arises from Hepatic artery proper (51-60%) left Hepatic 
artery (29-41%), common Hepatic artery (3.5%). Anterior and posterior 
branches from this artery anastamose with infrapyloric vessels & branches 
from supraduodenal Ar and gives blood supply to distal gastric unit (ie Antrum, 
Pylorus, 2.5.cm of Ist part of duodenum) and anastamose – with left gastric 
artery. 
RIGHT GASTROEPIPLOIC ARTERY:- 
Branch of Gastroduodenal Artery or its Continuation. Can sometimes 
arises from superior pancreatico-duodenal Artery or Superior Mesentric Artery 
gives branches to Infrapyloric branch and continues along greater curvature 
within the gastrocolic ligaments. It gives origin to Single or Paired anterior, 
posterior gastric branches. It anastamose exclusively with left gastric artery 
branches. In about 75% of cases, clearly anatamoses with the left 
Gastroepiploic artery, but not as seen with the left Gastric artery. It runs in 
front of common bile duct & descends along posterior surface of pancreatic 
head. 
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LEFT GASTRO EPIPLOIC ARTERY: 
Largest branch of splenic artery, through the gastrosplenic ligament                      
reach the stomach. It gives Anterior epiploic and Left epiploic branches, these 
branches along with the similar branches of Right Gastroepiploic, forms Arc of 
Barkow, along with branches from posterior epiploic and branches of Inferior 
Pancreatic Artery.                      
VENOUS SUPPLY OF STOMACH:- 
They mainly accompany the arteries, 
LYMPHATIC SUPPLY OF STOMACH:,- 
Lymphatic Supply of stomach follows the blood supply and is divided 
into four zones. lymph from the upper lesser curvature drains into superior 
gastric group and it drains into left gastric and paracardial nodes .Lymph from 
antral segment of lesser curvature of stomach drains into suprapyloric group of 
nodes and into Right supra pancreatic nodes .Pancreatico lineal group of 
Lymph nodes drains from greater curvature and then into left Gastroepiploic 
and splenic nodes .Lymph along right gastroepiploic vessels drains into inferior 
gastric / subpyloric group of nodes. Lymph from all these 4 zones drains into 
celiac group of nodes and into thoracic duct.  
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 NERVE SUPPLY OF STOMACH :- 
Parasympathetic innervations to the stomach is through the vagus and 
acetylcholine is the neurotransmitter. Vagus through Anterior and posterior 
branches supplies the stomach. 
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PIC 11.NERVE SUPPLY OF STOMACH 
 
       Anterior vagus near the Gastro esophageal junction, gives branches 
to the lesser curvature, and continues  as Anterior nerve  of Latarget along the 
Lesser curvature. 
Posterior vagus gives branches to celiac plexus and it continues 
similarly  along posterior side as nerve of latarjet terminates near the incisura 
angularis as “crow foot” give branches to Antropyloric region.  
Vagal nerves are more than 2 in 50% of patients .Near the esophageal 
Hiatus Criminal nerve of Grassi is the branch of posterior Vagus supplying 
posterior part of Fundus.  It arises above the Oesophageal Hiatus and it is 
missed during Truncal or Highly selective Vagotomy (HSV) 
The Sympathetic nerve supply of stomach is through T5-T10. It travels 
via splanchnic nerves to celiac ganglion.  Nerves from the Celiac ganglion 
reaches the stomach through the pathway of blood vessels. 
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LAYERS OF STOMACH:- 
SEROSA:- 
Visceral peritoneum forms serosa, provides tensile strength to gastric 
anastamosis. Microscopic or gross peritoneal metastasis are common if the 
tumour penetrate the serosa. 
MUSCULAR LAYER:  
Also called as Muscularis externa, It consists of following layers. 
1. Middle Circular layer:- 
-  It is complete and it is continuous with circular muscles of 
oesophagus and pylorus circular muscle. 
2. Outer Longitudinal Layer. 
- It is complete and it is continuous with. esophagus and duodenal 
Longitudinal Layer. 
3 . Inner Oblique Layer:- 
 It is incomplete. 
Auerbach myentric plexus are rich network of autonomic ganglia 
occupying muscularis propria.  Intestitial cells of cajal (Ice) which are 
pacemaker cells present in this Layer. 
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SUBMUCOSA:- 
Lies deep to muscularis mucosa, consists of blood vessels, collagen, 
Lymphatics, Inflammatory cells, ganglion cells and Submucosal plexus of 
meissners.  It is also called as Vascular layer. 
MUCOSA:- 
It constitutes the Inner Layer, Lined by various types of Columnar 
epithelial cells.  The epithelium , Lamina  propria and the muscularis mucosa,  
together called as Mucosa.  Simple columnar cells are present in cardia.  
Parietal (Oxyntic) and acid Secreating cells and chief pepsin - secreating cells 
are present in Fundus and body, Branched tubular gastric glands are present in 
cardia. Parietal (oxyntic) and acid secreting cells and chief pepsin secreating 
cells are present is fundus and body .Branched tubular gastric glands are 
present is lamina propria of fundus and body. 
PIC 12. LAYERS OF STOMACH 
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PIC 13.HISTOLOGY OF STOMACH 
 
 
RISK FACTORS FOR CA. STOMACH 
Acquired Factors:-  
- High salt consumption 
- High nitrate intake in dried, smoked foods, 
- Poorly prepared food (smoked salt cured) 
- Well water 
- Lack of refrigeration 
- Occupational 
- Rubber & coal workers 
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- Cigarette smoking 
-  H pylori infection 
- Ebstein bar virus  
- Prior gastric surgery for benign gastric ulcer disease. 
GENETIC FACTORS:- 
- Blood Group 
- Pernicious anaemia  
- Family History 
- Hereditary Nonpolyposis colon cancer 
- Li-Fraumeni syndrome 
H-PYLORI INFECTION:- 
- H pylori has strong association with gastric adenocarcinoma 
arising in antrum. 
- Many studies demonstrates that H pylori is associated with 
double the risk of carcinoma mechanism by which H pylori acts 
is unclear however it produce chronic atrophic gastritis leads to a 
Low acid environment leading to Metaplasia and dysplasia 
18 
 
studies shows that only 5% of H pylori infected persons develops 
carcinoma occur 10 years . 
- studies also shows that infection with cag A strains, produces 
more inflammation is stomach associated with increase risk of 
carcinoma . 
PATHOLOGY :- 
About 95% of all neoplasms are Adenocarinoma, other tumours are rare 
it includes squamous cell carcinoma, Adenoacanthoma, Carcinoid tumours and 
Leiomyosarcoma. There is increase is incidence of association between H 
pylori and mucosa associated lymphoid tissue lymphomas.  
EARLY GASTRIC CANCER:- 
Defined as Adenocarcinoma confined to mucosa and submucosa, 
irrespective of Lymphnode Status, About 70% of early gastic carers are well 
differentiated Adenocarcinoma about 30% are pooly differentiated About 95% 
have overall cure rate japanese classified based on this.  
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ADVANCED GASTRIC CARCINOMA : 
Bormann divides Gastric carcinoma based on macroscopic appearance it 
invades muscularis termed as advanced Gastric carcinoma. 
- Type I :- Polypoidal / fungating lesions.  
- Type II :- Ulcerative lesions surrounded by elevated borders. 
- Type III    :-Ulcerative lesions infiltrating to gastric wall 
- Type  IV    :Diffuse infiltrative lesions  
- Type   V   :Unclassifiable cancers  
     Type iv   when it involves entire stomach it is termed as Linitis 
plastica.   
PIC14.BORRMANNS CLASSIFICATION 
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BORDERS HISTOLOGICAL CLASSIFICATION:- 
According to differentiation of cells, independent of morphology type I 
[well differentiated] to Type 4 [anaplastic] type . 
MING CLASSIFICATION:- 
Classified into Expansive type which has favourable prognosis and 
infiltrating type, which has poor prognosis. 
LEVEEN’S CLASSIFICATION:- 
Proposed by Lauren in 1965. 
Divided into two types Intestinal (53%) and Diffuse types (33%) based 
on Histology.   
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TAB 19. LAURENS CLASSIFICATION 
INTESTINAL DIFFUSE 
Environmental 
Gastric atrophy, Intestinal Metaplasia 
M> W 
Incidence Increase with age. 
Formation of glands 
Spreads through Haematogenous 
Microsatellite Instability 
APC gene mutation 
P53, P16 Inactivation. 
   Familial 
    Blood Group.A 
W>M 
Occurs in Younger age. 
Poorly differentiated,Signet ring cells. 
  lymphatic/Transmural spread              
Decreased E- Cadherin 
P53, P16 Inactivation. 
 
INTESTINAL METAPLASIA:- 
It is defined as process of replacing gastric mucosa with mucosa 
resembling small Intestine. 
It is the intermediate step in development of stomach cancer in correa’s 
model.  It is due to the constant irritation of mucosa of stomach by risk factors 
such as H.Pylori. It is further classified into complete type I. Incomplete Type 
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II and Type III.  The differentiation is based on mucin core protein (MUC).  
Type III has Increased risk of progression to Ca. Stomach than Type I.   
Moleucular alterations such as Overexpression of cyclo- oxygenase, D2 
cyclins, P53 mutations, decreased P27 expression, Microsatellite.  Instability, 
alterations in CDX1 x CDX2 can cause Carcinoma. Recently in patients having 
gastric remnants with dysplasia, Spasmolytic polypeptide, led to concept of 
Spasmolytic-polypeptides expressing. Metaplasia(SPEM) may be precursor to 
Gastric adenocarcinoma. 
WHO CLASSIFICATION:-                      
1. Adenocarcinoma- 
- Papillary 
- Tubular 
-Mucinous 
-Signet ring cell. 
2. Adenosquamous cell carcinoma 
3. Squamous cell carcinoma  
4. Undifferentiated carcinoma. 
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PREDISPOSING FACTORS:- 
1. Gastric Polyps:- 
 - Malignancy is increased is polyps particularly Adenomas- 
Villous 
2. Pernicious Anaemia:- 
 - Achlorhydria due to destruction of oxyntic mucosa by auto 
immune mechanism is major risk factor, this will leads to 
destruction of chief and parietal cells which develops antral and 
Intestinal metaplasia. 6% of Pt will develops ca stomach. 
3. Mutations in CDHI:- 
 - E cadherin is calcium lon dependent adhesin moleucle present 
in tansmembrane responsible for epithelial cell interactions, so, 
when the expression is reduced as in cases of CDHI mutation, 
associated with tumour invasivenes.Reduced E-cadherin 
expression is noted in about 93% of carcinomas and it is 
associated with Undifferentiated, Diffuse type cancers therefore 
the persons who are carriers of these mutations are advised 
prophylactic gastrectomy. 
4.  p53 over expression – seen is 50% patients 
5.  Menetiers disease  
6.  Hypogammaglobulinaemia.. 
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CLINICAL PRESENTATION :- 
Most patients are diagnosed is advanced stage of disease due to presence 
of vague, non specific symptoms, Anorexia, fatigue, Epigastric discomfort, 
usually signs of advanced disease weight loss is a common symptom, about 
80% of patients have more than 10% decrease is body weight before 
confirming diagnosis location of tumour can cause specific symptoms presence 
of tumour in cardia presents with dysphagia. Diffuse infiltrative tumour 
presents with Early satiety due to loss of distensibility of Gastric wall. Antral 
carcinoma obstructing pylorus presents with persistent vomiting, 
Gastrointestinal bleeding presents is about 10% of patients Ascites, Jaundice, 
palpable mass indicates advanced or incurable disease symptoms sometimes 
related to spread of the disease Intestinal obstruction occurs is pt with diffuse 
peritoneal spread krukenberg’s tumour (large ovarian mass) of peritoneal 
implant is the pelvis (Blumer’s shelf) produces symptoms of Rectal 
obstruction. Sister mary joseph nodules is nodular metastasis is subcutaneous 
tissue around umbilicus. 
SITE DISTRIBUTION:- 
Ca stomach presents in both proximal and distal part.  In Developing 
countries Distal gastric cancers predominate, also in blacks and peoples in 
Lower Socioeconomic status. Dietary factors and H.pylori are most common 
causes of distal tumours.  Proximal cancers are common in developed countries 
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and also among whites and Higher Socioeconomic states.  Obesity and Gastro 
oesophageal reflux disease are most common cause.  Inspite of Increase in 
prevalence of proximal tumours, distal tumours are predominate in Japan . 
Reports from the west shows that there is a shift in site of occurance of 
malignancies of Gastric Cardia Increasing, which are contrary to Information 
from middle east and south asia. 
INVESTIGATIONS:- 
ENDOSCOPY:- 
- Best method to diagnose Ca stomach is by directly visible the mucosa 
of the stomach and tissue biopsy can be taken for Histopathological diagnosis.  
Several biopsies are taken from ulcer.  The diagnostic accuracy is increased if 
we add brush cytology to endoscopy. 
ENDOSCOPIC ULTRASOUND:- 
Its Main use is to stage the previously diagnosed stomach cancers. Used 
to evaluate T stage of the tumour and also about Surrounding lymphnodes.  
Accuracyof 90% in detecting T staging and for Nodal status it is 75%.  
COMPUTED TOMOGRAPHY:- 
CT Abdomen and pelvis is done to stage the patients.  In case of 
tumours arising in proximal part, CT chest is also taken. It evaluates tumour 
penetration, perigastric lymph node states, liver, and other organs metastasis, 
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and to detect peritoneal disease.  Recently use of water as an oral contrast- 
Helical Hydro CT, Increase the efficacy of CT in detecting tumour site and 
staging. 
4. PERITONEAL ANALYSIS:-  
Occult metastasis can be identified by cytological analysis of peritoneal 
fluid their prognosis is similar to the patients with macroscopic or visceral 
peritoneal metastasis. 
TUMOUR MARKERS : 
About one third of patients with ca stomach has elevated 
carcinoembryonic antigen [CEA]. Sensitivity is low, but if the levels are raised 
it correlates with the staging. Other markers used are CA19-9, CA50, CA72.4. 
Combination of these markers increase the sensitivity. Most studies in tumour 
markers directed towards prognostic power of pre operative serum 
concentrations. Results of few studies reported that use of CEA, CA19-9, in 
follow up of the patients, suggesting that measurement of this markers is useful 
in early detection of recurrence. 
POSITRON EMISSON TOMOGRAPHY: 
Based on the uptake of 5 fluorodeoxy glucose radioactive material by 
cancerous cells. But in stomach carcinoma there are some drawbacks due to 
glucose transporter 1 major transport of FDG into tumour cells which is rarely 
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present in mucinous and signet ring type this will leads to false negative 
imaging. 
LAPROSCOPY: 
Staging laproscopy is used in the pre treatment evaluation, of patients in 
detecting CT occult metastatic disease. Since CT cannot diagnose metastasis of 
less than 5mm and it also directly visualize peritoneal and visceral surfaces, 
and for detecting metastasis peritoneal cytology and laproscopic USG can also 
done. 
STAGING: 
American joint committee on cancer /International union against cancer 
[AJCC/UICC] is the staging system currently in use. 
PRIMARY TUMOUR 
Tx: Primary tumour cannot be assessed 
T0: no evidence of primary tumour 
Tis: carcinoma in situ: intra epithelial tumour without invasion of the 
lamina propria 
T1: Tumour invades lamina propria or submucosa 
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T2: Tumour invades the muscularis propria or the submucosa 
 T2a:Tumour invades muscularis propria 
 T2b:Tumour invades subserosa 
T3: Tumour penetrates the serosa(visceral peritoneum) without invading 
adjacent structures 
T4: Tumour invades adjacent structures. 
REGIONAL LYMPH NODES 
Nx: Regional lymph nodes cannot be assessed 
N0: No regional lymph node metastasis 
N1:Metastasis in 1-6 regional lymph nodes 
N2:Metastasis in 7-15 regional lymph nodes 
N3:Metastasis in more than 15 regional lymph nodes. 
DISTANT METASTASIS 
Mx: Distant metastasis cannot be assessed 
M0: No distant metastasis 
M1: Distant metastasis. 
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AJCC STAGING 
Stage 0 (Tis,N0,M0) 
Stage 1a (T1, NO,MO)  
Stage1b (T1,NI,MO;T2A,N0,M0;T2B,NO,MO) 
StageІ І (T 1,N2,MO;T2A,NI,MO;T2B,N1,M;T3,NO,MO) 
StageІІІА (T2A,N2,MO;T2B,N2,MO;T3,NI,MO;T4,NO,MO) 
StageІІІВ (T3,N2,MO) 
StageІV (T4,N1,MO; T4,N2,M0; T4,N3,MO; T1,N3,MO;T2,N3,M0; 
T3,N3,M0; Any T, ANY N, M1) 
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JAPANESE STAGING : 
Japanese classification of ca stomach was published in 1998.it gives 
more detail information than the AJCC staging. On the basis of clinical, 
surgical, pathological and final staging [prefixes c, s, p, f]. It also includes 
classification system for early gastric cancer. It classifies lymph node into four 
categories based on ha relation to primary tumour and anatomical location. 
Group 1: perigastric lymph nodes ( nodal station 1-6). 
Group 2: lymph nodes along proximal left gastric artery(station 7), 
common hepatic artery(station 8), celiac axis(station 9), splenic artery (station 
11), proper hepatic artery (station 12). 
Group 3: para aortic lymph nodes (station 16). 
TUMOUR STAGE:T 
T1: Tumour invasion of mucosa, and/or muscularismucosa, submucosa. 
T2: Tumour invasion of muscularis propria or sub serosa. 
T3: Tumour penetrates serosa. 
T4: invasion of adjacent organs. 
Tx: unknown. 
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NODAL STAGE :N 
N0: No evidence of lymph node metastasis . 
N1: Metastasis to group 1 nodes. 
N2: Metastasis to group 2 nodes. 
N3: Metastasis to group 3 nodes. 
Nx: unknown. 
HEPATIC METASTASIS STAGE:H 
H0: No liver metastasis. 
H1: Liver metastasis. 
H2: unknown. 
PERITONEAL METASTASIS STAGE:P 
P0: No peritoneal metastasis. 
P1: Peritoneal metastasis. 
Px: Unknown. 
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PERITONAL CYTOLOGY STAGE:CY 
CY0: Benign or intermediate cells in cytology. 
CY1: Malignant cells in cytology. 
CY2: Cytology was not performed. 
OTHER DISTANT METASTASIS(M): 
M0: No other distant metastasis. 
M1: Distant metastasis other than liver, peritonel and cytology 
measures. 
M2: Unknown. 
STAGE GROUPING: 
T1 N0 N1 N2 N3 
T2 IA IB II  
T3 IB II IIIA  
T4 II IIIA IIIB IV 
H1, P1, CY1, MI IIIA IIIB   
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RESECTION CLASSIFICATION: 
First described in 1994 by hermaneck. 
R0: No gross microscopic or residual disease. 
R1: Microscopic residual disease. 
R2: Gross residual disease. 
Some authors includes R staging as to complement the TNM staging, 
since survival can be increased by extent of resection of the tumour. 
CLASSIFICATION OF OESOPHAGO GASTRIC JUNCTION 
TUMOURS: 
Proposed by siewart and stein commonly known as SIEWART 
classification. 
TYPE1: Adenocarcinoma of distal oesophagus arises intestinal 
metaplasia of oesophagus [Barrrets oesophagus], infiltrate into gastro 
oesophageal junction. 
TYPE2: Adenocarcinoma of cardia, arises from the epithelium of cardia 
or from short segment with intestinal metaplasia at GE junction. 
TYPE3: Adenocarcinoma of subcardial stomach, infiltrate the 
oesophago gastric junction or distal oesophagus from below. 
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PATTERNS OF SPREAD: 
Direct spread: 
It penetrates the muscularis propria and serosa and involves the liver, 
colon, pancreas. 
Lymphatic spread: 
Occurs by tumour penetration and emboli to the affected group of nodes, 
it is very extensive can appear in left supra clavicular nodes (Troissies sign). 
Nodal metastasis does not indicates systemic dissemination. 
Haematogenous spread: 
It first spread to the liver and then into the lungs and bone. It is 
uncommon in the absence of lymph node metastasis. 
Trans peritoneal spread: 
It indicates incurability occurs once serosa is breached and tumour 
involves the peritoneum, commonly manifests as ascites, in advanced disease 
peritoneal spread can be palpated rectally or abdominaly as ‘shelf’. 
Involvement of ovaries (krukenberg tumour), or into umbilicus (sister josephs 
nodule). 
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SURGICAL TREATMENT : 
EARLY GASTRIC CANCER: 
Japanese classified early gastric cancer on the basis of endoscopic 
appearance. 
Type0I: Protruded type 
Type0 IIa: Superficialy elevated. 
Type0 IIb : Flat type 
Type0 IIc: Superficialy depressed 
Type 0 III : Excavated. 
ENDOSCOPIC MUCOSAL RESECTION : 
In 75% of cases of early gastric cancer complete resection can be 
achieved by this technique. It involve injection of fluid in the submucosal space 
and tumour is resected under endoscopic guidance. It should be offered only to 
the patients with low metastatic potential, well differentiated Type IIa, Type IIc 
lesions less than 3 cm in diameter. 
LIMITED SURGICAL RESECTION : 
Alternative to gastrectomy in patients with early gastric cancers. Patients 
with small intra mucosal tumours (less than 3 cm) and with non ulcerated intra 
mucosal tumours are candidates of this procedure. It includes gastrotomy with 
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local excision performed with full thickness mural excision aided by intra 
operative gastroscopy to localize the tumour. 
GASTRECTOMY : 
Patients having intra mucosal tumours with poor histological 
differentiation or size more than 3cm which is penetrated the submucosa or 
beyond are the candidates for gastrectomy with lymph node dissection. It 
allows pathological staging and local theraphy in high risk patients. 
PROXIMAL TUMOURS : 
Surgical treatment of proximal tumour is based on the SIEWARTS 
classification. They are usually advanced at the time of prognosis and 
associated with poor prognosis. 
Type I : oesophageal resection with marginal 10 cm clearence. 
Type II : Oesophago gastrectomy. 
Type III : Total gastrectomy with reconstruction. 
Total gastrectomy had no survival benefit over proximal or distal 
gastrectomy. If the tumour is completely removed with negative margins. 
MIDBODY TUMOURS : 
Treatment includes total gastrectomy with regional lymph adenectomy. 
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DISTAL TUMOURS : 
Treatment is distal subtotal gastrectomy with lymph adenectomy. 
Subtotal gastrectomy involves resection of three fourth of stomach includes 
majority of lesser curvature. 
 
DISTAL CARCINOMA 
SURGICAL PROCEDURES : 
TOTAL GASTRECTOMY : 
Indicated for proximal gastric tumours and extensive lesions Linitis 
plastic and for tumours where adequate marginal clearance of 4-6 cm is not 
possible by subtotal gastrectomy. Upper midline or bilateral roof top incision is 
made and thorough examination of abdominal organs is made. First step is 
detachment of greater omentum from transverse mesocolon along the avascular 
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plane about one cm from the bowel. The omentum and anterior leaf of 
transverse meso colon is removed along the stomach. On the right of 
dissection, right gastro epiploic vessels are ligated at the origin and sub pyloric 
nodes are excised. Then anterior layer of pancreatic capsule is removed and 
dissection is continued laterally where short gastric vessels are divided. Liver is 
retracted and gastro hepatic ligament is identified and is divided to access 
esophageal hiatus. 
 
 
The peritoneal reflection on the liver is continued along the right side 
and lesser sac is entered to gain access to level 12 lymph nodes where tape is 
hold around hepatic artery where significant number of lymph nodes are 
excised. Right gastric artery arising from it are identified and ligated near its 
origin. Duodenum is fully kocherised to allow access for retro pancreatic and 
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hepato duodenal region. Duodenum is divided and closed to give access to 
infra pyloric group of lymph nodes .  
 
DIVISION OF DUODENUM 
Cephalad portion of stomach is elevated and it exposes celiac plexus and 
left gastric artery. Left gastric artery is divided near its origin to hold lesser 
curve arterial arcade and lymph nodes are removed. On the greater curvature 
remaining short gastric vessels are divided close to spleenic hilum and lymph 
nodes are removed en bloc. Stomach is fully mobilized and stay sutures are 
introduced in greater and lesser curvature and distal esophagus. Non crushing 
clamp is applied proximal to esophageal stay sutures and esophagus is divided. 
There are many options for reconstruction. Commonly used is roux en y loop 
reconstruction. Roux en y loop reconstruction is end to side esophago jejuno 
anastomosis. Jejunal loop is divided and distal end is brought through 
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transverse meso colon and end to side anastomosis is done with single layer of 
mono filament absorbable sutures or with circular stapler. Proximal end of 
jejunum is anastomosed 40-50 cm downstream to reduce the reflux.  
PROXIMAL GASTRECTOMY  
Midline incision is made in abdomen. Esophageal hatus is identified by 
retracting the left lobe lateral segment of liver and diaphragmatic hiatus was 
incised. Retro peritoneal attachments to the diaphragm are incised on the left 
side and the esophagus is mobilized and retracted up and forwards and resected  
based on tumour extension. For extensive cardiac lesions spleen is mobilized 
and spleenectomy is done. For spleenic mobilization short gastric vessel are 
ligated close to spleenic hilum and resection is done forward alond posterior 
surface. It exposes celiac plexus and left gastric artery, lymph nodes along 
lesser curvature are dissected. Care should be taken not to de vascularise lesser 
curvature. Stomach is divided with GIA 60 OR TA stapler in oblique fashion.  
SUB TOTAL GASTRECTOMY 
For tumours involving pylorus and distal one third of stomach , sub total 
gastrectomy with lymph node dissection (D2 D3 Lymphadenectomy) is done. 
It is having low peri operative morbidity and mortality. Surgical steps are 
similar to total gastrectomy except final step of dividing short gastric vessels 
which is not done. Once resection and lymphadenectomy in done, e 
construction is performed with Roux en y loop anastomosis or Billroth II. 
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EXTENT OF LYMPHADENECTOMY: 
Japanese research society for ca stomach classified lymph nodes 
draining stomach into D1(stations 3 to 6), D2( stations 1,2,7,8,11) , D3(station 
9.10,12). Standard surgery for ca stomach in Asia is D2 gastrectomy involves 
extensive lymph node resection . (D1, D2). D2 resection removes peritoneum 
over the pancreas and anterior meso colon in addition to D2 resection.  
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 RESECTED SPECIMEN OF CA STOMACH 
 
CUT SURFACE 
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PALLIATIVE SURGERIES 
It is done in case of advanced ca stomach to minimise the bleeding and 
to relieve gastric outlet obstruction.  
Palliative gastrectomy 
Anterior gastro jejunostomy 
Laser ablation 
Endoscopic placement of metallic stents  
SURGICAL COMPLICATIONS: 
Anastomotic leak  (5-20%) 
Dumping syndrome(10%) 
Bleeding (0.5-6%) 
Pulmonary complications (3-50%) 
Infection (3-20%) 
Renal complications(1-5%) 
SURGICAL OUTCOME: 
5 year survival rate of stomach cancer is analysed based on National 
cancer institute SEER data base classified based on the stage. 
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Stage IA   -   70% 
Stage IB   -  57% 
Stage IIA  -  46% 
Stage IIB  - 33% 
Stage IIIA -  20% 
Stage IIIB – 14% 
Stage IIIC – 9% 
Stage IV    -  4% 
NEO ADJUVANT CHEMOTHERAPY: 
Given before surgery. It reduces the tumour seedling during surgery. 
Drugs used are etoposide, epirubicin, cisplatin, 5- fluoro uracil, adriamycin and 
methotrexate. Many trials are conducted in evaluating neo adjuvant 
chemotherapy. But there is no decrease in operative morbidity and mortality 
with this treatment.  
INTRA PERITONEAL CHEMOTHERAPY: 
Intra peritoneal chemotherapy of mitomycin c along with hyperthermia 
is given to prevent high risk of peritoneal metastasis which was initial cause for 
treatment failure. Since about 50% gastric cancer patients who undergone 
curative resection have clinically evident peritoneal metastasis.  
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ADJUVANT CHEMO RADIOTHERAPY: 
Combining 5 fluoro uracil (15 mg/kg/day bolus ) for three days with 40 
gy of external beam radiation . There is significant increase in survival when 
combined with radiotherapy alone. 5 fu act as a radio sensitizer. Patient who 
undergone radiotherapy have a 5 year survival rate of 20% vs 5% per cent 
survival rate in patients undergoing surgery alone. Loco regional recurrence 
also decreased from 54% to 39% in combined modality treatment.  
TREATMENT OF ADVANCED DISEASE(STAGE IV) 
SURGERY FOR PALLIATION : 
Survival rate for patients with advanced gastric cancer are poor. It 
should provide symptomatic relief and minimize the morbidity . operative 
mortality was 25% for gastro jejunostomy. 20% for palliative partial subtotal 
gastrectomy and 27% for proximal palliative gastrectomy. The most fatal 
complication following surgery is anastamotic leak.  
CHEMOTHERAPY: 
Multi drug regimens are now evaluated for gastric cancer. Combination 
therapy includes FAM(5FU,Adriamycin, methotrexate), FAMTX(5FU, 
adriamycin, methotrexate, etoposide), and 5 fluoro uracil, irinotecan, epirubicin 
cisplatin 5 fu, 5 fu irinotecan leucovarin, cisplatin plus irinotecan,  
5 fu leucovarin oxaliplatin (FOLFOX). 
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RADIOTHERAPY: 
Limited to palliate symptoms such as bleeding, pain which are 
secondary to tumour infiltration. No studies have evaluated the use of 
radiotherapy in locally recurrent or metastatic carcinoma of stomach.  
TARGETED THERAPIES: 
 Bevacizumab: 
It is the monoclonal antibody against vascular endothelial growth factor 
receptors (VEGF). It can be given along with cytotoxic chemotherapy even in 
primary gastric cancer.  
Tyrosine kinase inhibitor: 
Erlotinib and gefitinib, tyrosine kinase inhibitors are evaluated for gastro 
esophageal junction and gastric cancers. Epidermal growth factor receptor 
antibody cetuximab also under the study as a single or in combination with 
systemic chemotherapy. 
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METHODOLOGY 
The present study was undertaken at Government Mohan 
Kumaramangalam Medical College Hospital Salem from period of and 
December 2011 to August 2013. It includes those patients presenting to the in 
and outpatient department GMKMCH, Salem. 
MATERIALS 
9 Patients presenting to our hospital during the study period and 
who are found eligible for this study are  included.  
9 36 Cases of carcinoma stomach was studied during this period 
9 Details  of  36 patients  with  carcinoma stomach  was collected 
and followed based on various surgical treatment methods used. 
9 Cancer recurrence after surgery and benign lesion were excluded 
from the study. 
9 Age,  Gender, Symptoms, Signs and Surgical treatments are 
recorded in pre structured proforma.    
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9 Site of the tumours is classified based on following , 
1. OG junction 
2. Fundus & Cardia 
3. Body 
4. Antrum 
9 Relationship of tumour marker (CEA) and its association were 
included in this study. 
9 Borrmans classification and WHO classification and its relation 
to site of Tumour were included in this study. 
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DATA ANALYSIS 
AGE PREVALENCE: 
Carcinoma of stomach is disease of older age, and its incidence is 
increasing with increase in age. In our study maximum number of cases  are 
seen between, 55-64 yrs, youngest is 33 and oldest is 74. 
TABLE 1 : AGE DISTRIBUTION 
AGE PRESENT STUDY 
TOTAL % M F 
< 25 0 0 0 0 
25-34- 1 77% - 1 
35-44 4 11.11% 4 - 
45-54 7 19.44% 5 2 
55-64 18 50% 10 8 
65-74 6 16.66% 5 1 
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PIC 1. AGE DISTRIBUTION 
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SEX DISTRIBUTION:- 
Ca Stomach is common in males. In this study male female ratio is 3:1. 
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TABLE 2: SEX DISTRIBUTION 
 PRESENT STUDY 
SEX CASES % 
MALE 24 66.66 
FEMALE 12 33.33 
 
 
Male
67%
female
33%
SEX DISTRIBUTION
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RISK FACTORS:- 
TABLE 3 : RISK FACTORS AND ITS RELATION TO SITE 
SITE SMOKING ALCOHOL 
SMOKED 
FOODS 
OG junction 3 2 1 
Cardia & Fundus - - 2 
Body 4 3 2 
Pyloric antrum 11 12 12 
Linitis plastica - - - 
 
9 In male 100% of OG junction tumours are associated with 
smoking and is antral tumour 68.75%, 100% of tumours in body 
are associated with smoking. 
9 Smoked food shows increase in association with antral growth. 
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SITE :-  
In our study common site of Ca stomach is pyloric antrum .  pyloric 
antrum constitutes 21 out  of 36 cases. 
Study was is concordance with cherian et al (2007) & swarman et al 
studies . 
But the study was contradictory to increase in incidence of proximal 
growth in western countries  
Finally this study indicates that there is increase in distal growth than the 
proximal growth in our region. 
  
54 
 
SITE DISTRIBUTION : 
TABLE 4.SITE DISTRIBUTION 
SITE No of cases % 
OG   Junction                    3                   8.33 
Cardia and  fundus                   3                  8.33 
Body                    8                22.22 
Antrum                   21                58.33 
Linitis plastic                  1                  2.77 
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GENDER DISTRIBUTION ACCORDING TO SITE : 
Based on gender distribution site are evaluated. 
TABLE 5.GENDER DISTRIBUTION ACCORDING TO SITE 
SITE MALE FEMALE RATIO 
OG Junction 3 0 3 
Cardia and fundus 1 2 0.5 
Body 4 4 1 
Antrum 16 5 4.1 
Linitis plastica 1 0 1 
 
The ratio of male : female in cancers involving proximal stomach, body, 
antrum, OG junction was 0.5:1:4:1:3 
This was not in concordance with study conducted by Cherian et al, 
ratio is 3:2:3:4  respectively 
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INVESTIGATIONS: 
TABLE 6.INVESTIGATIONS 
SITE Endoscopy USG BA meal BA swallow 
OG Junction 100% _ _ _ 
Cardia and 
fundus 
100% _ _ _ 
Body 87.5% 12.5% _ _ 
Antrum 95% 40% _ _ 
Linitis plastica 100% _ _ 100% 
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PIC 4.INVESTIGATIONS RELATED TO SITE 
Endoscopy and biopsy was done in all cases   
It shows 100% in detecting OG junction and proximal tumour growths, 
87.5% in body and 95% in antrum  
Ultrasound has similarity of detecting 12.5% of body and 4o% of antral 
growth. 
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Carcino embryonic antigen: 
12 cases are positive for carcino embryonic antigen 
TOTAL CASES CEA Positive Negative 
36  12 24 
 
About 33% of cases are positive for carcino embryonic antigen. 
SYMPTOMS : 
TABLE 7. SYMPTOMS 
Symptoms 
Total Male=24 Female=12 
Cases  % Cases  % Cases  % 
Abdominal pain 28 77.77 20 83.33 8 66.66 
Nausea/ vomiting 29 80.55 21 87.5 8 66.66 
Weight loss  30 83.33 18 75 12 100 
Anorexia 14 38.88 10 41.66 4 33.33 
Early satiety 16 44.44 11 45.83 5 41.66 
Dysphagia 12 33.33 11 45.83 1 8.3 
Melena  6 16.66 4 35 2 1.66 
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Male patients commonly presents with abdominal pain and vomiting in 
about 80% of cases. 
Female patients commonly presents with weight loss which is seen in 
100% of cases. 
Melena is common in males than the females. 
PIC 5.SYMPTOM ANALYSIS IN MALE AND FEMALE : 
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TABLE 8.COMPARISON OF SYMPTOMS WITH SITE OF TUMOUR : 
SYMPTOM Total 
SITE 
ANTRUM (21) BODY(8) FUNDUS (3) OG JUNCTION (3) 
CASES % CASES % CASES % CASES % 
Abdominal  pain  28 20 95.2 4 50 3 100 1 33.3 
Nausea/ vomiting 29 21 100 5 62.5 2 66.6 1 33.3 
Weight loss 30 21 100 5 62.5 3 100 1 33.3 
Anorexia  14 12 57.14 1 12.5 1 33.3   
Early satiety  16 12 57.14 3 37.5 1 33.3   
Dysphagia  12 5 23.80 1 12.5 2 66.6 2 66.66 
Melena 6 2 9.5 2 25 2 66.6   
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Antral growth predominantly presents with nausea, vomiting, weight 
loss and abdominal pain.  
Dysphagia is reported in 24% of cases.  
Growth in body presents with nausea, vomiting and weight loss 
predominantly.  
Growth arising from fundus and OG junction has dysphagia, abdominal 
pain and weight loss as predominant symptoms.  
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SIGNS : 
TABLE 9.SIGNS 
SYMPTOMS 
TOTAL MALE FEMALE 
CASES % CASES % CASES % 
Anaemia 29 80.55 21 87.5 8 66.66 
Jaundice 7 19.44 6 25 1 8.33 
Lymphadenopathy 13 36.11 12 5. 1 8.33 
Mass 15 41.66 10 41.66 5 41.66 
VGP 21 58.33 17 70.83 4 33.3 
Ascites 8 22.22 5 20.83 3 25 
   
In both females and male, anaemia is the predominant sign. 
 Palpable mass was noted in about 41% of both male and female.  
20% of patients presents with jaundice .   
Visible  gastric peristalsis is predominant in 70% of males and 33% of 
females.  
Advanced stage of disease represented by ascites was noted in 20% of 
males and 25% of females. 
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COMPARISION OF SIGNS IN BOTH SEXES 
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TABLE 8. COMPARISON OF SIGNS WITH SITE OF TUMOUR : 
SYMPTOM Total 
SITE 
ANTRUM(21) BODY(8) FUNDUS(3) OG JUNCTION (3) 
CASES % CASES % CASES % CASES % 
Anaemia  29 19 90.47 4 50 3 100 3 100 
Icterus 7 6 28.57 0 0 0 _ 1 33.3 
Mass 15 10 47.61 4 50 1 33.3 _ _ 
VGP 21 19 90.47 2 25 0 _ _ _ 
Ascites 8 5 23.80 2 25 0 _ _ _ 
Lymphadenopathy  13 9 42.85 2 25 1 33.3 1 33.3 
  
Anaemia is present in 100% of proximal tumours. 
 In tumours arising from antrum, anaemia, VGP, followed by abdominal mass is major presentation.  
In tumours arising in body , mass and anaemia are major presentation.  
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Preliminary Investigations: 
Investigations Total Male Female 
Hb (gm%) 29 21 8 
Elevated LFT 7 6 1 
CXR - - - 
 
Among preliminary investigations Hb was reduced in 29 patients among 
which 21 are males and 8 are females. 
Among liver function test deranged in 7 patients among which 6 are 
males and 1 female 
DURATION OF SYMPTOMS: 
 Total <1 month 1-3 months 3-6 months >6 months 
Abdominal pain 28 20 4 4 - 
Nausea/vomiting 29 6 6 14 3 
Dysphagia 12 - 4 6 2 
Weight loss 31 - - 6 25 
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Among symptoms, abdominal pain presents maximally in less than 1 
month duration, vomiting presents maximally in 3-6 month. 
Dysphagia maximally in 3-6 months and weight loss commonly seen in 
age group >6 month. 
MACROSCOPY : 
TABLE 11.BORRMANNS CLASSIFICATION 
BORRMANN 
TYPE 
           TOTAL         MALE (24)   FEMALE (12) 
CASES         % CASES         % CASES        % 
              I 10 27.7 7 29.16 3 25 
            II 20 55.5 11 45.83 9 75 
           III 4 11.1 4 16.66 0 0 
           IV 2 5.5 0 0 2 16.66 
  
Predominant  macroscopic type was Borrmann type II followed by type 
I and type III.  
In both males and females predominant type was type II  
 Females had higher percentage of advanced lesion.  
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STAGING : 
Classified on the basis of AJCC Staging, the patient are categorized on 
this basis. 
TABLE 12.STAGING 
STAGE TOTAL NO OF 
CASES 
% 
Ia _ _ 
Ib _ _ 
 
II 23 63.88 
III a 5 19.44 
III b _ _ 
IV 8 16.66 
 
      About 63% of patients in this study are presented with stage II 
disease and about 16% are presented with stage IV disease. 
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STAGING AND ITS ASSOCIATION WITH SITE : 
TABLE 13.STAGE IN RELATION TO SITE 
 STAGE 
Ia 
STAGE 
II b 
STAGE 
II 
STAGE 
IIIa 
STAGE 
IIIb 
STAGE 
IV 
OG junction _ _ 1 2(66%) -  
Cardia and 
fundus 
_ _ 3 0 -  
Body  _ _ 3 3 - 2 
Antrum  _ _ 16(76%) 0 - 5 
Linitis 
plastic 
_ _ _   1 
 
In this study , 63% of cases present with stage II disease. 
 In OG junction tumours  66%  presents with stage III disease. 
 In antral disease 76% presents with stage II disease.  
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NODAL STAGING 
     
STAGING NO OF PATIENTS % 
NO 26 72.2 
NI 6 16.6 
N2 4 11.11 
N3 _ _ 
METASTASIS 
    STAGING   NO OF PATIENTS                  % 
             M0              28            77.77 
             M1               8           22.22 
  
About  72% of patients present with NO status. 
16% presents with N1 status and about 66.66 % presents with 
metastasis.  
 
 
71 
 
SURGICAL TREATMENT : 
TABLE 16.SURGICAL MODALITIES 
Total gastrectomy 6 16.66 % 
Subtotal gastrectomy with Roux en y anastomosis 15 41.66 % 
Palliative anterior gastro jejunostomy 6 16.66 % 
Feeding jejunostomy 8 22.22 % 
Lap sleeve gastrectomy 1 27 % 
       
Total gastrectomy  was done in 16.66% patients.  
Subtotal gastrectomy was done in 41% patients 
Palliative procedures such as anterior gastro jejunostomy done in 16% . 
 22% undergone feeding jejunostomy.  
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PATHOLOGY : 
TABLE 17.PATHOLOGY 
TYPE          TOTAL                MALE            FEMALE 
CASES % CASES % CASES % 
Well differentiated 
adenocarcinoma 
19 52.7 14 58.3 5 41.6 
Moderately 
differentiated 
adeno carcinoma 
11 30.5 7 29.16 4 33.3 
Poorly 
differentiated 
adenocarcinoma 
6 16.6 3 12.5 3 25 
Undifferentiated 
adeno carcinoma 0 0 _ _ _ _ 
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   Majority are well differentiated  adenocarcinoma with 52.7%.  
 In both males and females majority are well differentiated 
adenocarcinoma. 
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PATHOLOGY IN TUMOUR SITE : 
TABLE 18.PATHOLGY IN RELATION TO TUMOUR SITE 
DIFFEREN 
TIATION TOTAL ANTRUM BODY PROXIMAL 
OG 
JUNCTION
Well     19        10          5         2              2 
Moderately      11         7          2          1              _ 
Poorly       6         4         1          _              1 
Undifferentiated       _          _          _           _               _ 
 
FOLLOW UP: 
All patients are followed up after surgery patients of  stage II disease are 
advised chemotherapy. 
 FOLLOW UP 6 MONTHS DEFAULT 
STAGE II  23 10 13 
STAGE III 5 1 4 
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OBSERVATION 
Stomach cancer is increasing with increase in age maximum between 
the age group of 55-64 yrs.  
Male has more preponderence  than the females with the ratio of 2:1. 
Incidence of Distal tumours is increasing than the proximal tumours. 
Proximal tumours are increasing in associated with smoking.  
Antral group of tumours predominantly presents with nausea, vomiting, 
abdominal pain and weight loss.  
Proximal tumours commonly presents with anaemia seen in all the 
cases.  
Female patients commonly presents with advanced stage of disease.          
Majority of patients presents with stage II disease.  
OG junction tumours commonly presents with stage III disease. 
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CONCLUSION 
There is a increase in incidence of carcinoma stomach with increasing in 
age.  
There is increase in incidence in males than the females.  
Distal tumours continue to be more common than the proximal tumours. 
Endoscopy is very useful modality in diagnosing carcinoma stomach 
even in early stages. 
Most patients are presents in the advanced stage of disease indicating 
there is lack of proper screening for the disease.  
Curative subtotal gastrectomy or distal gastrectomy is associated with 
good quality of life if the tumour is operable. 
Preventive strategies offers best opportunity for control of disease such 
as Antioxidants, H.pylori therapy. 
ANNEXURES 
A CLINICAL STUDY OF GASTRIC CARCINOMA 
PROFORMA 
Case No: 
Name:                                                 Age:                                                Sex: 
Occupation:                                                                       IP No: 
Symptoms: 
a. Abdominal Pain:                                      b. Nausea/ Vomiting 
c. Weight loss:                                             d. Anorexia: 
e. Early satiety:                                            f. Jaundice: 
g. Dysphagia:                                               h. Malena: 
i. Other symptoms: 
Past History : Prior gastric surgery 
Family History: 
Personal History: 
Tobacco use/Pan chewing: 
Alcohol: 
GPE: 
Built :     Nourishment :   Hydration : 
Pallor :  Icterus:                  Lymphadenopathy: 
Vitals: BP PR: 
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SYSTEMIC EXAMINATION: 
P/A 
INSPECTION: 
a. Distention/fullness: 
b. Dilated veins: 
c. Visible mass: 
d. Visible gastric peristalsis: 
e. Umblicus:  
f. Movement of abdominal quadrants: 
PALPATION: 
Mass  
a. site  
b. size 
c. shape 
d. surface 
e. borders 
f. consistency 
g. mobility 
h. movement with respiration 
i. succusion splash: 
j. organomegaly 
k. left supra clavicular nodes 
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PERCUSSION: 
Over the mass 
Liver span  
Shifting dullness 
AUSCULTATION 
P/R 
Other system Examination: 
RS  : 
CVS :  
CNS : 
Investigations 
Routine :  Hemoglobin-   ESR- 
  Total count-   Differential count- 
 CT- BT- 
 Blood urea:  
 Serum creatinine: 
  Random blood sugar:  
  Liver function tests:  
  Serum electrolytes:    
 CEA: 
  Chest X –Ray: 
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Special investigations: 
 Upper GI Endoscopy : 
 USG Abdomen : 
  CT Scan Abomen : 
  Biopsy : 
Treatment: 
  Surgery : 
  Operative procedure : 
  Findings :  
 Post operative period : 
 Examination of the specimen: 
 Site of growth : pylorus/Antrum/Body/Fundus/Cardiooesophageal junction 
 Type  of growth  :  Polypoidal/Fungating   
  Ulcerative with elevated/depressed edges 
  Diffuse/ Infiltrated 
  Unclassified 
 Histopathology :  
 Chemotherapy: 
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ABBREVIATIONS 
AP  ABDOMINAL PAIN  
GJ  GASTROJEJUNOSTOMY 
WL  WEIGHT LOSS  
JJ  JEJUNO JEJUNOSTOMY  
ES  EARLY SATIETY 
FJ  FEEDING JEJUNOSTOMY  
RY      ROUX EN Y  
OJ  OESOPHAGO JEJUNOSTOMY   
SER SEROSA INVOLVEMENT  
WD  WELL DIFFERENTIATED  
MD  MODERATELY DIFFERENTIATED  
PD POORLY DIFFERENTIATED  
GC GREATER CURVATURE  
V  VOMITING   
LC  LESSER CURVATURE  
DY  DYSPHAGIA  
FF  FREEFLUID 
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ANO ANOREXIA 
STD  SOFT TISSUE DENSITY                                             
A  ALCOHOL 
PI PANCREATIC INVOLVEMENT 
S  SMOKING 
ULC  ULCERATIVE 
DE  DISTAL ESOPHAGUS 
MAS    MASS 
PS  PROXIMAL STOMACH                                    
AN  ANTRUM  
BO  BODY 
M  MALENA 
J  JAUNDICE  
PYL PYLORES  
PG PERIGASTRIC 
PAN PANCREAS 
ED EDEMATOUS 
IRR IRREGULAR 
vi 
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PATIENT CONSENT FORM 
Study Title: Clinical Study of Carcinoma Stomach in patients presenting 
in GMKMCH Salem. 
Study Centre:  Department Of General Surgery, GMKMCH Salem 
Participant Name:    Age:    Sex:  I.P. No: 
I confirm that I have understood the purpose of surgical procedure for 
the above study. I have the opportunity to ask the question and all my questions 
and doubts have been answered to my satisfaction. 
I have been explained about the possible complications that may occur 
during surgical and post-surgical procedure. I understand that my participation 
in the study is voluntary and that I am free to withdraw at any time without 
giving any reason. 
I understand that investigator, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both in 
respect to the current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study. I understand that my identity 
will not be revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from the study. 
I hereby consent to participate in this study for various surgical 
procedures and their outcomes. 
Time: 
Date:     Signature / thumb impression of patient 
Place:     Patient’s Name: 
